TLDR
- Moderna agreed to pay $950 million upfront to Arbutus Biopharma and Genevant Sciences to settle patent disputes over its COVID vaccine technology.
- If Moderna loses a pending federal appeal, it will owe an additional $1.3 billion within 90 days.
- The settlement is the largest patent settlement in pharma history and second-largest across all industries.
- Moderna stock jumped 8.7% in after-hours trading to $54.15 following the announcement.
- Moderna now expects to end 2026 with $4.5–$5 billion in cash, with total liquidity of up to $5.9 billion.
Moderna’s long-running patent fight is finally over — and Wall Street liked what it heard.
The company announced late Tuesday it will pay $950 million in a lump sum to Arbutus Biopharma (ABUS) and privately held Genevant Sciences to resolve all global patent litigation over its Spikevax and mResvia vaccines.
The dispute centered on lipid nanoparticle (LNP) delivery technology, which is used to get mRNA into the body. Arbutus and Genevant sued Moderna, claiming it used their patented LNP tech without permission.
Arbutus shares fell 11% to $4.20 in after-hours trading after the news dropped.
The $950 million payment will be recorded as a charge in Q1 2026 and paid as a lump sum in Q3. Moderna will owe no future royalties after that payment.
There is still a contingency. Moderna is appealing to a federal circuit court, arguing limited liability as a government contractor. If it loses that appeal, it has agreed to pay up to an additional $1.3 billion within 90 days.
The total potential payout of $2.25 billion is still well below what some had feared. Analysts at William Blair noted investors had been bracing for close to $5 billion in projected liability, which would have raised serious liquidity concerns.
As part of the deal, Genevant is granting Moderna a global non-exclusive license to its LNP delivery technology for certain mRNA vaccines. Genevant also agreed not to sue Moderna over certain patents going forward.
What This Means for Moderna’s Cash Position
Including the settlement, Moderna now expects to end 2026 with $4.5 billion to $5 billion in cash and equivalents. It also retains access to up to $900 million under an existing credit facility, bringing total projected liquidity to between $5.4 billion and $5.9 billion.
CEO Stéphane Bancel said the deal removes uncertainty and lets the company focus on what’s ahead.
Bancel expects Moderna to return to revenue growth by the end of 2026. The company is targeting approval of its flu-plus-COVID combination vaccine and a standalone flu vaccine this year.
Pipeline and Clinical Milestones Ahead
Several clinical trial results in cancer and rare diseases are also expected in 2026, which William Blair analysts called potential “new long-term growth drivers.”
The settlement resolves what had been a persistent overhang on the stock. Moderna’s mRNA platform is core to its broader pipeline beyond COVID.
Arbutus and Genevant described the deal as the largest disclosed patent settlement in pharma history and the second-largest across any industry.
Genevant CEO James Heyes called it “enormously gratifying” to be recognized for the company’s contribution to pandemic response.
Moderna’s stock is up more than 60% over the past 12 months, compared to roughly 17% gains for the S&P 500.
The $950 million lump-sum payment is due in Q3 2026.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
